Innovating Works

INTRAVACC

Desconocido
GA-VAX: Advancing a vaccine targeting genetic amyotrophic lateral sclerosis (C9orf72 ALS) to the clinical st... INTRAVACC BV participó en un HORIZON EUROPE: HORIZON-EIC-2021-TRANSITIONOPEN-01 Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that is triggered by protein aggregation in the brain and spinal co...
2022-03-22 - 2025-01-31 | Financiado
TRANSVAC-DS: DESIGN STUDY FOR A EUROPEAN VACCINE INFRASTRUCTURE INTRAVACC BV participó en un H2020: H2020-SC5-2018-2019-2020 The TRANSVAC-DS project further builds on the outstanding success of EC-funded projects:TRANSVAC1 and TRANSVAC2 and proposes the establishme...
2020-06-09 - 2023-02-28 | Financiado
TRANSVAC2: European Vaccine Research and Development Infrastructure INTRAVACC BV participó en un H2020: H2020-INFRAIA-2016-2017 TRANSVAC2 is the follow-up project to its successful predecessor project TRANSVAC, the European Network of Vaccine Research and Development...
2017-07-28 - 2023-04-30 | Financiado
VAC2VAC: Vaccine lot to Vaccine lot comparison by consistency testing. INTRAVACC BV participó en un H2020: H2020-JTI-IMI2-2015-03-two-stage Lot release testing of established vaccines relies on using animal models. Many of these models were developed decades ago and reflect the l...
2016-04-14 - 2022-02-28 | Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.